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Imiquimod is considered one of the treatments of choice 
for low-risk superficial basal cell carcinoma (sBCC) and 
an alternative option for non-superficial tumours when 
surgery is contraindicated or not feasible (1–3). 
In addition to its well-known value in the diagnosis of 
BCC, dermoscopy has recently been shown to provide 
valid information about the histopathological subtype 
or the presence of clinically undetectable pigmentation 
(4–6). The aim of the present study was to investigate 
whether dermoscopic criteria (especially ulceration) of 
the primary tumour can predict a favourable response of 
BCC to imiquimod.
MATERIALS AND METHODS
This was a retrospective study conducted in a referral unit for 
skin cancer diagnosis and management. Inclusion criteria were: 
(i) availability of clinical and dermoscopic images of the lesion 
before treatment; (ii) a complete treatment cycle of imiquimod 
5%, 5 days per week for 6 weeks; (iii) available medical records 
of the post-treatment follow-up visit conducted one month after 
the end of treatment; and (iv) available medical records of the 
follow-up visit conducted one year after the end of treatment for 
lesions assessed as completely healed.
Patients’ data and the anatomical sites of the lesions were recor-
ded. The dermoscopic images were evaluated by 2 independent 
investigators (MU and AL) and a third 
investigator (GA) was involved in cases 
of disagreement. Selection of dermoscopic 
criteria to be evaluated was based on the 
avail able literature and on our primary 
hypothesis that ulceration might represent 
a predictor of response to imiquimod. In 
our analysis, the presence of erosions/
ulceration was included as a categorical 
variable with the following possible values: 
0 (no erosions/ulceration), 1 (solitary small 
erosion), 2 (multiple small erosions) and 3 
(large ulceration) (Fig. 1).
The treatment outcome was recorded 
after a single cycle of imiquimod, as 
evaluated at the post-treatment visit. For 
completely responding BCCs, the report of 
the visit conducted one year after the end 
of treatment was recorded.
Both patients and lesions were used as 
units of analysis, and correlations between 
patients and lesions were examined to 
compensate for possible data clustering (7). 
Parametric or non-parametric tests were 
used, following normality explorations. 
Collinearity was assessed (Spearman’s rho coefficient). Relative 
risks were calculated for all dichotomous variables. Categorical 
pseudo-variables were coded for categorical variables. Crude and 
adjusted odds ratios (OR; with 95% confidence intervals [CI]) 
were calculated by univariate and conditional multivariate logistic 
regression, respectively. The type I error probability associated 
with all tests was set at < 0.05. All statistical calculations were 
made with SPSS 22.0 (IBM SPSS, USA).
RESULTS
A total of 134 lesions from 85 patients were included. 
The majority of BCCs (115/134, 85.8%) were diagnosed 
clinically and/or dermoscopically, whereas 19 lesions 
(14.2%) were diagnosed histopathologically. The mean 
follow-up period after the end of treatment was 12.5 
months, ranging between one month (for not completely 
responding tumours) and 56 months. The most common 
lesion location was the head and neck (105/134, 78.4%), 
followed by the trunk (28/134, 20.9%) and the extremi-
ties (1/134, 0.7%). 
At the post-treatment evaluation visit, 83 of 134 
(61.9%) BCCs were assessed as having responded com-
pletely, since all the clinical and dermoscopic criteria of 
BCC had disappeared. Indeed, none of these tumours 
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Fig. 1. Examples of dermoscopic ulceration visualized at × 10 magnification (DermLite 
Foto). a) absent; b) single, small erosion; c) multiple, small erosions; d) large ulceration. 
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recurred during the 1-year follow-up period. Of the 
remaining lesions, 14 (10.4%) were assessed as having 
responded partially, 20 (14.9%) as non-responding, and 
in 14 lesions (10.4%) the assessment was not conclusive. 
The response to treatment was found to correlate with 
the anatomical site of the trunk (r = –0.302, p < 0.001) and 
with the presence of dermoscopic ulceration (r = –0.297, 
p = 0.001). In detail, the presence of a solitary small 
erosion posed a 7-fold higher probability for complete 
response (OR 7.00, 95% CI: 1.25–39.15, p = 0.027), the 
presence of multiple small erosions posed a 38-fold 
higher odd for complete response (OR 38.89, 95% CI: 
7.52–201.04, p < 0.001) and the presence of large ulcera-
tion was associated with an 8-fold increased probability 
for complete response (OR 8.17, 95% CI: 1.63–40.85, 
p = 0.011) (Fig. S11). This effect of ulceration was further 
amplified in the multivariate adjusted model, as shown 
in Table I.
DISCUSSION
Imiquimod is an attractive modality routinely used in the 
everyday practice to treat BCC. Its cost-effectiveness has 
been assessed as superior to surgery (2), which becomes 
particularly relevant in the light of evidence suggesting 
that non-melanoma skin cancer is among the 5 most 
costly cancers (8). However, the response rates of BCC 
to imiquimod have been reported to vary significantly, 
namely from 65% to 100% (9–11). Our findings suggest 
that dermoscopy could provide an indication of the pos-
sibility of response to imiquimod, thus optimizing the 
utility of the drug.
The finding that multiple small erosions represent 
the strongest predictor of response to imiquimod can 
probably be explained by the fact that this dermoscopic 
criterion is commonly seen in superficial tumours (5, 
12–14). However, large ulceration, although predictive 
of non-superficial subtypes (5, 12–14), was also found 
to predict a favourable response. Indeed, the multivariate 
analysis revealed that the presence of ulceration was a 
potent predictor of response to imiquimod irrespective 
of the subtype, suggesting that ulceration predicts a fa-
vourable response both for superficial and non-superficial 
BCCs.
This study has several limitations. First, the retro-
spective design is subject to evaluation bias. To address 
this limitation, the evaluation of dermoscopic images 
was performed by 2 independent investigators who 
were blinded for treatment outcome. Secondly, the pre-
operative diagnosis and the post-treatment outcome were 
not histopathologically confirmed. However, a recent 
study (15) showed that the post-treatment detection of 
BCC-related criteria is absolutely predictive of residual 
disease. Similarly, the same study suggested that the 
absence of any BCC-related dermoscopic criterion can 
safely predict a complete clearance of BCC after imiqui-
mod therapy. Indeed, none of the tumours assessed as 
completely healed at post-treatment evaluation recurred 
during one year of follow-up. However, we still cannot 
rule out that some of the tumours may recur later.
In conclusion, the results of this study suggest that the 
dermoscopic detection of erosions or ulceration in BCC 
represents a strong predictor of favourable response to 
imiquimod. The results might help clinicians to better 
select BCCs to be treated with imiquimod, thus opti-
mizing the utility of this modality in everyday practice.
The authors declare no conflicts of interest.
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